Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes
Improve blood sugar regulation : GLP-1 agonists enhance insulin sensitivity and reduce glucose production in the liver, making them effective for individuals with type 2 diabetes
OSA patients who received tirzepatide initiated CPAP therapy about 83% less often than those who did not receive the drug
PubMed Central, Lin, Jonathan H., et al
The immunomodulatory effects of prebiotics and synbiotics supplemented in ovo have been reported
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
